Specifically, we engineered the MYCN non-amplified NB cell line SK-N-AS to conditionally knock down (cKD) RB1 through a doxycycline-inducible CRISPRi system (SK-N-AS cKD RB1) (Figure S6). The gene discussed is MYCN; the disease is neuroblastoma.